Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease by Piotr Chrusciel et al.
REVIEW ARTICLE
Defining the Role of Trimetazidine in the Treatment
of Cardiovascular Disorders: Some Insights on Its Role in Heart
Failure and Peripheral Artery Disease
Piotr Chrusciel • Jacek Rysz • Maciej Banach
Published online: 6 June 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Trimetazidine is a cytoprotective drug whose
cardiovascular effectiveness, especially in patients with
stable ischemic heart disease, has been the source of much
controversy in recent years; some have gone so far as to
treat the medication as a ‘placebo drug’ whose new side
effects, such as Parkinsonian symptoms, outweigh its
benefits. This article is an attempt to present the recent key
studies, including meta-analyses, on the use of trimetazi-
dine in chronic heart failure, also in patients with diabetes
mellitus and arrhythmia, as well as in peripheral artery
disease. This paper also includes the most recent European
Society of Cardiology guidelines, including those of 2013,
on the use of trimetazidine in cardiovascular disease.
Key Points
Trimetazidine is well established in stable coronary
artery disease
Preliminary evidence suggests that trimetazidine
might be an effective drug in diabetic and non-
diabetic patients with chronic heart failure and in
those with peripheral artery disease
Trimetazidine has been generally well tolerated in
clinical trials but some recently reported adverse
drug reactions require careful evaluation in studies
with longer follow-up
1 Trimetazidine Mechanism of Action
Trimetazidine is a cytoprotective drug that normalizes
metabolic disturbances in low-flow ischemia via several—
not yet fully understood—mechanisms of action. The best
known trimetazidine mechanism of action is its capacity to
inhibit b-oxidation of free fatty acid (FFA) [1]. FFA oxi-
dation provides more energy, but it is associated with
increased oxygen consumption. When oxygen is in low
supply, the oxidative processes of FFA and glucose are
disrupted—paradoxically leading to an increased rate of
FFA b-oxidation associated with even greater oxygen
consumption—while glucose metabolism decreases, which
results in lactate accumulation and, in extreme cases,
development of metabolic acidosis [1, 2]. By selectively
inhibiting the enzyme long-chain 3-ketoacyl coenzyme A
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thiolase (LC 3-KAT), which is the final enzyme in the FFA
b-oxidation pathway, trimetazidine increases the metabolic
rate of glucose [2]. Trimetazidine also increases pyruvate
dehydrogenase activity, which starts restoring homeostasis
between glucose oxidation and glycolysis, imbalanced
during ischaemia [1–3]. This results in decreased oxygen
consumption during adenosine-50-triphosphate (ATP) syn-
thesis, hydrogen ion production, limited increase of intra-
cellular acidosis, and reduced calcium ion accumulation [1,
3, 4]. Correcting energy insufficiency leads to reduced
accumulation of sodium in cardiomyocyte cytoplasm,
decreased formation of reactive oxygen species (ROS), and
reduced neutrophil infiltration [5, 6]. This results in cellular
membrane stabilization [7, 8].
Another trimetazidine mechanism of action that may be
important for cardiovascular disease patients, including
subjects with chronic heart failure (CHF), is its direct
inhibition of cardiac fibrosis [9]. Compensatory cardiac
hypertrophy eventually leads to fibrosis and heart failure
(HF). This mechanism may be promoted by the connective
tissue growth factor (CTGF), which has been confirmed in
an experimental model in rats with valvular HF [9]. In
comparison with placebo (physiological saline), trimetazi-
dine reduced collagen accumulation, CTGF expression in
cardiac fibroblasts, nicotinamide adenine dinucleotide
phosphate-oxidase (NADPH oxidase) levels, and ROS
production [9]. The phenomenon of trimetazidine effects
on endothelin 1 (ET-1) metabolism and release by non-
selective blockade of ET-1 receptors has also been
observed (still undocumented in clinical studies) (Table 1)
[10].
Another trimetazidine mechanism of action, particularly
relevant in acute myocardial ischemia, is an improved
mechanical resistance of the sarcolemma [11, 12]. During
reperfusion following an acute ischaemic episode, the
sarcolemma is subjected to significant reoxygenation-
induced mechanical stress due to tissue oedema. Increased
sarcolemmal resistance of living cells in the reperfused
zone reduces the area of myocardial infarction-related
necrosis, which protects myocardial cells against apoptosis
[11, 12]. Trimetazidine may also restore mitochondrial
function, impaired following ischaemia, since the trime-
tazidine binding site to the mitochondrial membrane has
been identified. This confirms anti-ischaemic properties of
the drug (Table 1) [13, 14].
2 Trimetazidine in Stable Coronary Artery Disease
Many patients with angina pectoris do not receive adequate
antianginal therapy because of haemodynamic intolerance
or chronotropic incompetence. Trimetazidine as an addi-
tional therapy may represent an optional treatment to be
used in association with first-line antianginal drugs, espe-
cially in those patients for whom optimal control of
symptoms cannot be achieved with other antianginal drugs.
The TRIMetazidine in POLand (TRIMPOL)-II study [15],
which was the continuation of the TRIMPOL-I study [16],
the study by Sellier and Broustet [17] and the most
recent—the VASCO (Efficacy of trimetazidine on func-
tional capacity in symptomatic patients with stable exer-
tional angina) study [18]—were the studies providing
evidence generated in support of trimetazidine as an add-on
to beta-blockers in symptomatic patients with angina pec-
toris. Two other studies by Manchanda and Krishnaswami
[19, 20] and Manchanda [19, 20] supported the efficacy of
trimetazidine as an additional therapy to calcium channel
blockers.
In the double-blind, placebo-controlled TRIMPOL-II
study, trimetazidine 60 mg/day was added to metoprolol
(50 mg bid) for 12 weeks in a group of 426 patients with
stable angina pectoris [15]. The authors observed a sig-
nificant improvement in the trimetazidine group (as
compared with placebo) for the following parameters:
total exercise duration (?20.1 s, p = 0.023), total work-
load (?0.54 metabolic equivalents [METs], p = 0.001),
time to 1-mm ST-segment depression (?33.4 s,
p = 0.003), time to onset of angina (?33.9 s, p \ 0.001),
angina attacks/week (-0.73, p = 0.014), and the neces-
sity of short-acting nitrates administration per week (-
0.63, p = 0.032) [15]. The TRIMPOL-II study showed
that trimetazidine added to metoprolol significantly
improved exercise capacity and exercise-induced myo-
cardial ischaemia. The efficacy was also confirmed in
patients at maximal dose of metoprolol and in patients
with recurrent angina [15]. In another important double-
blind, placebo-controlled study, Sellier and Broustet
evaluated the efficacy of trimetazidine modified release
(MR) 70 mg/day in a group of 223 patients with angina
pectoris who were insufficiently controlled with 50 mg/
day of atenolol after 2 months of therapy [17]. After
Table 1 The main cytoprotective mechanisms of trimetazidine
FFA breakdown inhibition and glucose breakdown stimulation
Reduction in the amount of oxygen necessary for ATP production
Reduction in the cellular accumulation of lactic acid and H?
Reduction in the cellular accumulation of Na? and Ca2?
Reduction in ATP losses for maintaining ion homeostasis
Reduction of adverse effects of overloading cells with calcium
Anti-radical effect
Reduction of granulocyte infiltration to the ischaemic and
reperfused area of the myocardium
Cardiomyocyte apoptosis inhibition
Adapted and modified from Banach [3]
ATP adenosine-50-triphosphate, FFA free fatty acid
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8 weeks, the authors observed a significant increase in the
time to 1-mm ST-segment depression in exercise tests
(?34.4 s, p = 0.03) in the trimetazidine group in com-
parison with the placebo group [17]. Finally, the above-
mentioned VASCO study was the largest randomized
controlled study conducted with trimetazidine [18]. The
patients with stable angina receiving 50 mg of atenolol
were randomized to the addition of trimetazidine MR 70
or 140 mg or placebo for a 12-week period. In the cohort
of all chronic stable angina patients, trimetazidine sig-
nificantly improved total exercise duration (TED) com-
pared with baseline and placebo. Both doses of
trimetazidine significantly increased TED (p = 0.0044
and p = 0.0338 for trimetazidine 140 mg/day and trime-
tazidine 70 mg/day, respectively). A greater TED
improvement was observed in trimetazidine 140 mg/day
than in trimetazidine 70 mg/day, although the difference
was not significant. Amongst patients with limiting angina
during exercise test, both doses of trimetazidine signifi-
cantly improved both time to 1-mm ST-segment depres-
sion and TED [18].
The role of trimetazidine in angina pectoris patients was
also analysed in the meta-analyses. In 2003, Marzilli and
Klein [21] published the first meta-analysis of 12 trials
including 868 patients. Trimetazidine was found to sig-
nificantly increase exercise duration to 1-mm ST-segment
depression on the exercise test, and to reduce weekly epi-
sodes of angina, both as monotherapy and as add-on ther-
apy [21]. Ciapponi et al. [22] conducted a meta-analysis of
23 trials with 1,378 patients with stable angina. The authors
showed that trimetazidine reduced the number of weekly
angina attacks (p \ 0.0001) and weekly nitroglycerine
tablet consumption (p \ 0.0001) and improved exercise
time to 1-mm segment depression on the exercise test
(p = 0.0002), compared with placebo [22]. In the largest
meta-analysis conducted on the effects of trimetazidine in
stable angina pectoris patients, Danchin et al. [23] evalu-
ated 218 trials with a total 19,028 patients, including the
results of the VASCO trial. Trimetazidine significantly
improved exercise tolerance, weekly angina episodes, and
use of short-acting nitrates when compared with placebo
[23]. Finally, for the comparison of trimetazidine with
other antianginal agents without an effect on heart rate,
network meta-analyses were performed [24]. In these
analyses, trimetazidine had similar anti-ischemic effects to
dihydropyridines, long-acting nitrates, nicorandil, and ra-
nolazine, both as monotherapy and as add-on therapy. The
findings of this robust meta-analysis strongly supported the
indication of trimetazidine as an effective agent for the
management of stable angina [24]. These results also
provided strong arguments for the position of trimetazidine
in the current guidelines for the management of patients
with stable angina (see below).
3 Trimetazidine in Chronic Heart Failure
Trimetazidine has a rather well documented effect on
improving the left ventricular systolic and diastolic func-
tion, although properly designed and controlled large
clinical trials with sufficient follow-up are still scant [17,
25, 26]. A number of available reports have also demon-
strated clinical improvement in patients based on various
parameters—improved exercise tolerance, improved qual-
ity of life, or reduced New York Heart Association
(NYHA) HF class [25–28]. Brottier et al. [26] showed that
6-month therapy with trimetazidine at 20 mg three times a
day in patients with NYHA class III/IV resulted in
improved left ventricular ejection fraction (LVEF) by 9 %
measured via radioactive isotope method, with simulta-
neous LVEF reduction by 16 % demonstrated in the pla-
cebo group (p = 0.018). Subsequent studies in CHF
patients showed similar results [27–31]. Recent publica-
tions do little to challenge these results. The 2006 paper by
Morgan et al. [32] based on an experimental HF model
additionally demonstrated that 12-week treatment with
trimetazidine reduced the levels of the atrial natriuretic
peptide (ANP), another biomarker of HF, admittedly not
measured in clinical practice. Fragasso et al. [33] assessed
the effect of adding trimetazidine (n = 20) or placebo
(n = 27) to conventional treatment in CHF patients fol-
lowed for a mean period of 13 months. The trimetazidine
group showed improvement in the NYHA HF class
(p \ 0.0001), left ventricular end-diastolic volume
(LVEDV) (from 98 ± 36 to 81 ± 27 mL; p = 0.04) and
LVEF (from 36 ± 7 to 43 ± 10 %; p = 0.002) [33].
Meanwhile, the placebo group showed deterioration of
these parameters, with increased left ventricular end-sys-
tolic volume (LVESV) (from 142 ± 43 to 156 ± 63 mL;
p = 0.20) and LVEDV (from 86 ± 34 to 104 ± 52 mL;
p = 0.10) as well as reduced LVEF (from 38 ± 7 to
34 ± 7 %; p = 0.02). As emphasized by the authors,
despite the small number of subjects enrolled in the study,
the results suggest a beneficial effect of trimetazidine
treatment; that is, inhibition of the natural course of CHF
that involves gradual deterioration of cardiac function on
conventional therapy alone [33]. In a subsequent study
involving 50 patients with ischaemic cardiomyopathy, 25
patients were assigned to receive conventional treatment
plus trimetazidine, while the remaining 25 patients con-
stituted the control group [34]. After a 6-month follow-up,
both groups achieved an insignificant reduction in NYHA
class. The group receiving trimetazidine demonstrated a
considerable reduction in brain natriuretic peptide (BNP)
levels (135 ± 22 vs 252 ± 44 pg/mL; p \ 0.001) and
cardiac troponin T (cTNT) (p \ 0.001), while the control
group showed increased plasma BNP levels (288 ± 46 vs
239 ± 59 pg/mL; p \ 0.02), with no significant changes in
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cTNT levels. Trimetazidine administration also resulted in
a significant improvement in exercise tolerance assessed
with a 6-min walk test (6MWT) (p \ 0.01); however, it
was not associated with a significant improvement in LV
systolic function (with LVEF values: 28 ± 4 %,
29 ± 5 %, and 32 ± 5 %, at baseline, after 1 month and
6 months, respectively) [34]. Similar results were achieved
by Sisakian et al. [35], who achieved even more promising
results of trimetazidine use in patients with ischaemic
cardiomyopathy. A total of 82 patients were included in
that study, with 42 patients (study group) receiving 35 mg
trimetazidine twice a day for 3 months on top of their
conventional treatment, and the remaining 42 patients
constituting the control group. Exercise test-based physical
capacity improved by 30 ± 20.7 m (from 215 ± 17.5 to
245 ± 20.7 m) in the trimetazidine group, versus
2.0 ± 18.85 m (from 208.2 ± 12.4 to 210.2 ± 14.2 m) in
the control group (p \ 0.001) [35]. An echocardiographic
examination in the trimetazidine group showed improved
LV systolic function (LVEF) by a mean of 3.5 ± 6.72 %
(to 38.0 ± 4.8 % from the baseline value of
34.5 ± 3.8 %), with the improvement in the control group
of only 0.8 ± 8.06 % (to 33.2 ± 5.8 % from the baseline
value of 32.4 ± 5.6 %) (p = 0.05) [35]. Belardinelli et al.
[36] additionally demonstrated the effect of trimetazidine
in essentially improved endothelium-dependent LV relax-
ation, assessed on the basis of reduced levels of plasma
malondialdehyde (MDA) (from 3.98 ± 0.69 to
2.15 ± 0.59 mmol/L) and lipid hydroperoxides (LOOHs)
(from 3.72 ± 0.9 to 2.06 ± 0.6 mmol/L) in comparison
with the placebo group (p \ 0.001 for both), which con-
stitutes some evidence for antioxidative properties of the
drug [36].
A very interesting study was published by Tuunanen
et al. in 2008 [37]. However, it was also very limited due to
the small number of included patients. The Finnish group
included 19 patients with dilated cardiomyopathy. A total
of 12 patients were included in the trimetazidine group and
seven patients from the control group received placebo. In
comparison with the placebo group, the trimetazidine
group demonstrated a greater improvement in LVEF (from
30.9 ± 8.5 to 34.8 ± 12 %; p = 0.027); moreover, inter-
estingly, an 11 % increase in high-density lipoprotein
(HDL) levels and reduced insulin resistance reflected in
lower blood glucose (p = 0.047) and blood insulin levels
(p = 0.031). However, the power of that study was insuf-
ficient to discuss any possible effects of trimetazidine on
the reduction of inflammatory processes or oxidative stress,
and thus, on any changes in HDL functionality either [38–
40]. In another study by Fragasso et al. [41] patients with
LV systolic dysfunction (n = 44) were randomized to
receive either conventional treatment (n = 19) or conven-
tional therapy plus trimetazidine (n = 25). At 3 months of
follow-up, trimetazidine administration versus conven-
tional treatment alone showed improved LVEF (from
35 ± 8 to 42 ± 11 % and from 35 ± 7 to 36 ± 6 %,
respectively; p = 0.02), reduced NYHA class
(p = 0.0001) and improved quality of life (p \ 0.0001).
The use of trimetazidine also led to a reduced rate of
energy expenditure (from 1,677 ± 264 to
1,580 ± 263 kcal/day; p = 0.038) [41].
Of note, the available data indicate that trimetazidine
treatment may be particularly important in patients with
CHF and concomitant diabetes mellitus [42, 43]. Similarly
to the data presented in the paper by Tuunanen et al. [37],
Fragasso et al. [29] demonstrated, by analysing 16 diabetic
patients with ischaemic cardiomyopathy, that the use of
trimetazidine 20 mg three times a day led to a significant
reduction in fasting blood glucose compared with placebo
after a 6- and 12-month follow-up (121 ± 30 vs
136 ± 40 mg/dL, respectively; p = 0.02 and
125 ± 36 mg/dL vs 140 ± 43 mg/dL; p = 0.19) with a
simultaneous reduction in insulin resistance [20]. However,
these results have not been confirmed in all available
papers. Indeed, Swedish investigators demonstrated that
the use of trimetazidine for over 1 month in diabetic
patients with CHF NYHA class II or III failed to show
superiority over conventional treatment [42]. Moreover,
there were no statistically significant differences between
trimetazidine and placebo groups in terms of exercise tol-
erance or LV function (LVEF assessment via tissue
Doppler imaging at rest and on exertion showed only a
slight change in favour of the study group) [42]. Despite
being a randomized, double-blind, controlled study, like
most of the earlier trimetazidine studies, it included only a
very small group of patients (n = 20), hence the authors’
statement should be treated with caution [42]. Conversely,
Gunes et al. [43] demonstrated more beneficial effects. The
authors emphasized the benefits of trimetazidine in terms
of improved LV systolic function in patients with diabetes
and ischaemic CHF. The paper demonstrated that the use
of trimetazidine resulted in improved LVEF both in the
diabetic (n = 14) and non-diabetic (n = 37) patients at
3 months of follow-up; however, the improvement of LV
systolic function was significantly greater in the group with
abnormal glucose metabolism (p \ 0.001) [43]. The study
consistently demonstrated beneficial effects of the drug,
particularly in this group of patients. Nonetheless, there is
still a question around the mechanism of action of trime-
tazidine that improves carbohydrate metabolism. Further
studies are needed to ultimately determine whether such a
relationship really exists. A very interesting suggestion was
presented by a group of Chinese authors who believe that
the use of trimetazidine at an early stage of abnormal
glucose metabolism in the form of impaired glucose tol-
erance or even at the pre-diabetes stage may prevent
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diabetic cardiomyopathy [44]. This results from the fact
that patients with abnormal glucose metabolism have sig-
nificantly reduced glucose and lactate metabolism as well
as increased fatty acid b-oxidation [45, 46]. The use of
trimetazidine at early stages of the disease could contribute
to glucose metabolism normalization, and the drug itself
could no longer be considered only in CHF treatment but
also in diabetic cardiomyopathy prevention [44]. Naturally,
these results must be confirmed in further studies.
Another important aspect is the effect of trimetazidine
treatment on electrocardiographic changes in CHF patients
and the associated reduction in electrophysiological risk
factors of atrial and ventricular arrhythmias, including
sudden cardiac death (SCD) [47–49]. Gunes et al. [47]
described the effect of trimetazidine on sinus rhythm var-
iability. Adding trimetazidine 20 mg three times a day to
conventional HF treatment for 3 months in a group of 30
patients resulted in improved ambulatory 24-hour EKG
parameters, such as the standard deviation of normal-to-
normal R-R intervals (SDNN) (97.3 ± 40.1 to
110.5 ± 29.2 ms; p = 0.049) and standard deviation of the
averages of normal-to-normal R–R intervals (SDANN)
(80.5 ± 29.0 to 98.3 ± 30.5 ms; p = 0.008). Moreover,
improved LV systolic function (increase in LVEF from
33.5 ± 5.1 to 42.5 ± 5.8 %; p \ 0.001) and an increase in
SDNN correlated with the increase in LVEF. In another
study of the same authors [48], they presented the effect of
6-months’ treatment with trimetazidine at 20 mg three
times a day in CHF patients (n = 36) on the P-wave
duration and dispersion—predictors of atrial fibrillation,
which is a factor increasing postoperative mortality in
patients undergoing coronary artery bypass grafting
(CABG) [49]. The authors demonstrated that added to
conventional treatment, trimetazidine results in reduced
P-wave duration (from 106.7 ± 15.8 to 102.2 ± 11.5 ms;
p = 0.006) and dispersion (from 57.2 ± 15.4 to
48.9 ± 10.1 ms; p \ 0.001), with a decrease in left atrial
size (from 41.5 ± 6.7 to 40.3 ± 6.1 mm; p \ 0.001) and
improved LVEF (from 32.7 ± 6.5 to 37.2 ± 5.5 %;
p = 0.036). Zemljic et al. [50] described the effect of tri-
metazidine on the corrected QT (QTc) interval duration in
patients with ischaemic CHF. This study included a total of
42 HF patients with NYHA class II and III, with 20 patients
receiving the conventional treatment and 22 subjects
receiving an additional 35 mg of trimetazidine two times a
day. At baseline, the groups did not differ significantly in
terms of the QTc intervals (p = 0.62); however, after 1
month of treatment, a statistically significant QTc interval
reduction was observed only in the trimetazidine group
(404 ± 36 ms; p = 0.0002) [50]. Cera et al. [51] studied
the effects of trimetazidine on the change in QTc duration
in CHF patients. The study included 13 patients receiving
conventional treatment and 17 patients additionally
receiving trimetazidine. The QTc interval was significantly
reduced in both groups, QT peak increased only in the
control group, Tpeak–Tend dispersion (Tp–Te–d) decreased
only in patients receiving trimetazidine. Based on CHF
aetiology, Tp–Te–d reduction was found to be statistically
significant only in patients with underlying ischaemic CHF
(65.00 ± 27.14 vs 36.67 ± 11.55 ms; p = 0.001). The
authors emphasize that the trimetazidine mechanism of
action responsible for this phenomenon is still unknown;
nonetheless, they indicate the possible benefits of trime-
tazidine in this group of patients, such as a decreased
incidence of ventricular arrhythmias [51].
None of the previous studies answered the question most
burning to physicians—whether trimetazidine reduces
overall mortality in CHF patients; that is, whether it is a
drug that may prolong survival. A post hoc analysis of the
Villa Pinid’Abruzzo Trimetazidine Trial [52] showed that,
in comparison with conventional therapy alone, the addi-
tion of trimetazidine significantly reduced the hospitaliza-
tion rate due to HF exacerbation (by 47 %; p = 0.002) and
overall mortality (by 56 %; p = 0.0047) at month 48 of
follow-up. Moreover, the trimetazidine group demonstrated
improvement in LVEF (p \ 0.001 at month 48 of follow-
up), increased exercise tolerance and reduction in NYHA
HF class [48]. However, the study was based on a small
group of 61 patients and, therefore, was not powered
enough to allow these results to be reliable [52]. In 2011,
Gao et al. [53] published a meta-analysis which covered 17
randomized studies from the period between 1966 and May
2010, including a total of 955 patients with CHF. In
comparison with placebo, trimetazidine administration was
associated with increased exercise tolerance (weighted
mean difference [WMD] 30.26 s; p \ 0.01), NYHA class
reduction (WMD 0.41; p \ 0.01), improved LVEF in
ischaemic HF (WMD 7.37 %; p \ 0.01) and non-ischae-
mic HF patients (WMD 8.72 %; p \ 0.01). Moreover, the
use of trimetazidine in the group of CHF patients reduced
the rate of CV events and hospitalizations (RR 0.42, 95 %
CI 0.30–0.58, p \ 0.00001), and most importantly, reduc-
tion in overall mortality was demonstrated (RR 0.29, 95 %
CI 0.17–0.49, p \ 0.00001) (Table 2). It must be empha-
sized that the studies included in that meta-analysis were
insufficiently powered to assess the effect of trimetazidine
on pre-determined endpoints, and therefore, the results of
this meta-analysis must not be considered as decisive [53].
One year later, Zhang et al. [54] presented another meta-
analysis on the use of trimetazidine in CHF patients. This
time, 16 randomized studies were evaluated, with 884
patients in the study group. Like the earlier meta-analysis,
this one demonstrated that the use of trimetazidine was
associated with improved LVEF (WMD 6.46 %,
p \ 0.0001), increased exercise tolerance (WMD 63.75 s,
p \ 0.0001), reduced NYHA class (WMD -0.57;
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p = 0.0003), decreased LVESV (WMD -6.67 mm,
p \ 0.0001) and LVEDV (WMD -6.05 mm, p \ 0.0001),
lowered BNP levels (WMD -203.40 pg/mL, p = 0.0002),
and reduced the rate of CV hospitalization (RR 0.43,
p = 0.03). However, no reduction in overall mortality was
observed (RR 0.47, p = 0.27) (Table 2) [54]. This meta-
analysis had similar limitations to those of the analysis
conducted by Gao et al. [53]. Very recently, in March
2013, Fragasso et al. [55] published the results of a large,
multicentre, retrospective study, including 669 CHF
patients (including 362 patients receiving trimetazidine). A
follow-up of 38.76 ± 15.66 months in the trimetazidine
group and 40.17 ± 15.53 months in the group receiving
conventional therapy alone demonstrated that the addition
of trimetazidine versus conventional therapy alone is
associated with reduced CV hospitalization rate (adjusted
hazard ratio [HR] 0.524, 95 % CI 0.352–0.781,
p = 0.001), CV mortality (HR 0.072, 95 % CI
0.019–0.268, p = 0.0001), as well as overall mortality (HR
0.102, 95 % CI 0.046–0.227, p = 0.0001) (Table 2) [55].
Despite these important results presenting trimetazidine
efficacy in CHF patients, we cannot recommend using
trimetazidine in this group of patients as a result of the
significant limitations connected with these studies—meta-
analyses based on unpowered studies and the retrospective
character of the analysis by Fragasso et al. A well designed,
randomized clinical study, placebo-controlled, with well
selected endpoints, appropriate patient group, and follow-
up duration is still needed to possibly recommend the use
of trimetazidine in HF patients.
4 Trimetazidine in Peripheral Artery Disease (PAD)
The benefits of using trimetazidine in peripheral artery
disease have not been well documented and are based on
individual studies. Several studies have reported a benefi-
cial effect of this drug on extending the intermittent clau-
dication distance [56–58]. One such study published in
2003 described anti-ischaemic effects of trimetazidine both
Table 2 Major studies with trimetazidine use in CHF patients
Authors Year Materials and methods Results
Gao et al. [53] 2011 17 randomized studies from the period
between 1966 and May 2010; 955 CHF
patients
In comparison with placebo, the use of trimetazidine results in:
• Increased exercise tolerance (WMD 30.26 s, p \ 0.01),
• Reduced NYHA class (WMD 0.41, p \ 0.01),
• Improved LVEF in ischaemic HF (WMD 7.37 %, p \ 0.01) and
non-ischaemic HF patients (WMD 8.72 %, p \ 0.01),
• Reduced rate of cardiovascular events and hospitalizations (RR 0.42,
95 % CI 0.30–0.58, p \ 0.00001),
• Reduced overall mortality (RR 0.29, 95 % CI 0.17–0.49,
p \ 0.00001)
Zhang et al. [54] 2012 16 randomized studies; 884 CHF patients Trimetazidine treatment results in:
• Improved ejection fraction (WMD 6.46 %, p \ 0.0001),
• Increased exercise tolerance (WMD 63.75 s, p \ 0.0001),
• Reduced NYHA class (WMD -0.57, p = 0.0003),
• Decreased LVESV (WMD -6.67 mm; p \ 0.0001) and LVEDV
(WMD -6.05 mm, p \ 0.0001),
• Lowered BNP levels (WMD -203.40 pg/mL, p = 0.0002),
• Reduced rate of cardiovascular hospitalization (RR 0.43, p = 0.03)
Trimetazidine continues to have no effect on overall mortality (RR
0.47, p = 0.27)
Fragasso et al. [55] 2013 A multicentre retrospective study; 669
CHF patients, including 362 patients
receiving trimetazidine. Follow-up
period: 38.76 ± 15.66 months in the
trimetazidine group and
40.17 ± 15.53 months in conventional
therapy alone group
Addition of trimetazidine in comparison with the conventional
treatment alone is associated with:
• Reduced rate of cardiovascular hospitalization (adjusted HR 0.524,
95 % CI 0.352–0.781, p = 0.001),
• Reduced cardiovascular mortality (HR 0.072, 95 % CI 0.019–0.268,
p = 0.0001),
• Reduced overall mortality (HR 0.102, 95 % CI 0.046–0.227,
p = 0.0001)
BNP brain natriuretic peptide, CHF cardiovascular heart disease, HF heart failure, LVEDV left ventricular end-diastolic volume, LVEF left
ventricular ejection fraction, LVESV left ventricular end-systolic volume, NYHA New York Heart Association, WMD weighted mean difference
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via coronary vessels (reduced rate of ischaemic attacks),
and peripheral vessels (expressed exactly in the extended
distance of intermittent claudication) [56]. The same effect
was described by other authors in 2006; they observed a
longer pain-free walking distance during an exercise test on
ranolazine treatment [57]. In the recent double-blind study
by Vitale et al. [58], 100 patients with intermittent clau-
dication randomized to receive trimetazidine or placebo
with a subsequent 3-month follow-up were included.
During the study, the patients exercised regularly, and the
assessment was based on measuring the length of maximal
walking distance (MWD) and the assessment of ankle-
brachial index (ABI), which were measured at baseline and
after 3 months of treatment. In a comparison of the tri-
metazidine and placebo groups, the groups did not differ at
baseline or at 3 months of follow-up in terms of ABI
(0.83 ± 0.04 vs 0.85 ± 0.03), while the value of MWD at
3 months of treatment was decisively greater in the group
receiving trimetazidine (23 vs 14 %, p \ 0.0001). How-
ever, the study was based on a relatively small group of
patients (although larger than in the previous reports) and
the follow-up period was insufficient to unequivocally
confirm beneficial effects of trimetazidine in this group of
patients [58]. On the other hand, however, that study was
the stepping stone to further trials on a larger group of
patients, with a longer follow-up, to finally evaluate the
potential role of trimetazidine in patients with atheroscle-
rotic lesions in peripheral arteries.
Among other interesting studies on peripheral arteries,
one noteworthy trial was conducted on an animal model,
which demonstrated a protective effect of trimetazidine on
retinal cells during ischaemia [59]. The authors showed
that the thickness of the overall retina from the outer to the
inner limiting membrane and outer retinal layers was sig-
nificantly greater after 15 and 30 days of reperfusion in
those rats that were treated with trimetazidine before the
retinal ischaemia incident, induced by increasing intraoc-
ular pressure to 160 mmHg for 60 minutes [59].
Moreover, there has been a recent study [60] suggesting,
based on experiments in diabetic rats, that the use of tri-
metazidine may decrease the intima-media ratio (IMR) in
the carotid artery after only 4 weeks of treatment, and this
effect was dose-dependent. In comparison with the control
group, trimetazidine at 20 mg/kg/day caused a greater IMR
reduction than at 10 mg/kg/day (p = 0.046 and p = 0.002,
respectively). Moreover, trimetazidine was demonstrated to
reduce the incidence of restenosis, via reduced smooth
muscle cell proliferation and enhanced rate of endotheli-
alization following a carotid artery injury due to balloon
expansion during angioplasty, with the proliferation index
of 34.2 ± 4.1 % in the control group, 29.4 ± 2.0 % in the
trimetazidine 10 mg group, and 15.4 ± 3.2 % in the tri-
metazidine 20 mg group (p \ 0.01) [60].
Based on these limited data, trimetazidine still cannot be
recommended or any conclusion drawn as to its effec-
tiveness in the treatment of peripheral artery disease.
Nonetheless, these results are promising and they offer
hope that some patients with peripheral artery disease
could also benefit from this drug; however, this requires
conducting further, large, and carefully designed studies.
5 Trimetazidine Adverse Drug Reactions
Trimetazidine has been generally very well tolerated in
clinical trials and usually only isolated cases of adverse
events (ADRs—adverse drug reactions) were observed
during trimetazidine treatment (mainly gastrointestinal
disturbances, vomiting, nausea) [61]. Some other very rare
and reversible adverse effects have also been described,
such as thrombocytopenia, agranulocytosis and liver dys-
function [62]. Other minor adverse effects (episodes of
headache) were also reported. Most of them were not
considered to be directly related to trimetazidine [62].
However, some recently reported ADRs require careful
evaluation in longer follow-up. The main identified tri-
metazidine-induced serious ADR is connected to Parkinson
syndrome and related symptoms (tremor) [61]. According
to available data, trimetazidine may worsen previously
diagnosed Parkinson’s disease and gait disorders in some
patients [61]. In the study of Martı´ Masso´ et al. [61], in 56
of the 130 patients who were treated with trimetazidine
(43 %), an adverse effect on motor function was detected
that had been induced or aggravated by one of the with-
drawn drugs. Drug-induced parkinsonism was detected in
20 of these patients (10 patients were being treated with
trimetazidine only, while the remaining 10 were simulta-
neously receiving other drugs potentially capable of
inducing parkinsonism). Treatment with trimetazidine
worsened previously diagnosed Parkinson’s disease in 12
patients, and gait disorders coupled with disequilibrium
was observed in 15 patients. Trimetazidine induced tremor
in nine patients [61].
The risk related to Parkinson syndrome that has been
identified in the postmarketing setting and in literature is
based on positive dechallenge of Parkinson symptoms after
the withdrawal of trimetazidine only, positive rechallenge,
essentially higher co-prescription of antiparkinson drugs in
trimetazidine group compared with control group and sig-
nificantly higher number of patients that begin antiparkin-
son drugs after the introduction of trimetazidine compared
with control group [24]. It is worth emphasizing that
extrapyramidal symptoms reported in patients receiving
trimetazidine have a very low prevalence (incidence of
0.36/100,000 person-years) and are generally reversible
after trimetazidine withdrawal. According to the European
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Medicines Agency (EMA), if trimetazidine-related par-
kinsonian symptoms persist more than 4 months after drug
discontinuation, a neurologist’s opinion should be sought
[24]. Parkinsonian symptoms (tremor, akinesia, hypertonia)
should be regularly investigated, especially in elderly
patients on trimetazidine. Patients receiving the treatment
over a very long time, mainly in cardiology indications,
aged more than 75 years old are from the group at the
highest risk of this complication occurrence. They may
have increased trimetazidine exposure due to age-related
decrease in renal function. In patients with severe renal
impairment (creatinine clearance \30 ml/min), trimetazi-
dine should not be used [24].
6 ESC Recommendations on the Use of Trimetazidine
in Cardiovascular Disease
The European Society of Cardiology (ESC) guidelines of
2013 take into consideration the possibility of using tri-
metazidine as treatment for stable coronary artery dis-
ease—however, this is a IIb recommendation [63]. The
current recommendations do not consider this treatment in
other cardiovascular diseases, such as CHF [64], acute
coronary syndromes [65, 66], or peripheral artery disease
[67].
7 Conclusions
The most documented effect of trimetazidine has been in
stable coronary artery disease, which has been demon-
strated by inclusion of this drug into the recommendations,
as well as in both diabetic and ischaemic CHF, which still
requires confirmation in large clinical studies. There are
still no answers to key questions as to the role of this drug
in selected cardiovascular conditions as well as whether
this drug can reduce mortality in any group of patients with
cardiovascular disease [68–72].
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